0001104659-21-132339.txt : 20211101 0001104659-21-132339.hdr.sgml : 20211101 20211101160537 ACCESSION NUMBER: 0001104659-21-132339 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211101 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211101 DATE AS OF CHANGE: 20211101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TELA Bio, Inc. CENTRAL INDEX KEY: 0001561921 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 455320061 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39130 FILM NUMBER: 211367155 BUSINESS ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY, SUITE 24 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 484-320-2930 MAIL ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY, SUITE 24 CITY: MALVERN STATE: PA ZIP: 19355 8-K 1 tm2131467d1_8k.htm FORM 8-K
0001561921 false 0001561921 2021-11-01 2021-11-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) 

of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 1, 2021

 

TELA Bio, Inc. 

(Exact name of registrant as specified in its charter)

 

Delaware   001-37526   45-5320061

(State or other jurisdiction of

incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

1 Great Valley Parkway, Suite 24

Malvern, Pennsylvania

 

    19355
(Address of principal executive offices)       (Zip Code)

 

Registrant’s telephone number, including area code: (484) 320-2930

 

Not Applicable 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   TELA   Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01 Other Events.

 

On November 1, 2021, TELA Bio, Inc. (the “Company”) issued a press release announcing that the Company has entered into a distribution agreement with Next Science, which grants the Company exclusive rights to sell and market Next Science’s proprietary antimicrobial surgical wash with XBIO® technology across the U.S. plastic reconstructive market. A copy of this press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

The following exhibit is being filed herewith:

 

Exhibit No.   Document
99.1   Press Release of TELA Bio, Inc., dated November 1, 2021.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  TELA BIO, INC.
   
  By: /s/ Antony Koblish
  Name: Antony Koblish
  Title: President, Chief Executive Officer and Director

 

Date: November 1, 2021

 

 

EX-99.1 2 tm2131467d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

TELA Bio and Next Science Enter into Exclusive Distribution Agreement in the

Plastic Reconstructive Market for Advanced Anti-Biofilm Surgical Wash

 

Agreement includes exclusive right to sell and market Next Science's proprietary no rinse

antimicrobial solution in the US and first right of negotiation for EU market upon CE Approval.

 

MALVERN, PA, November 1, 2021 -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced it has entered into a distribution agreement with Next Science, a medical technology company, granting TELA exclusive rights to sell and market Next Science's proprietary antimicrobial surgical wash with XBIO® technology across the US plastic reconstructive market. Additionally, TELA Bio received a first right of negotiation for the EU market upon successful CE approval.

 

Next Science's XBIO Technology delivers an advanced option for surgical infection control by addressing the biofilms that make bacteria more resistant to traditional antimicrobial agents, disinfectants, and host immune defenses. The no-rinse delivery allows the solution to provide over five hours of ongoing protection against bacterial biofilms. With no known bacterial resistance, the XBIO Technology provides broad spectrum efficacy with exceptional rates of pathogen removal.

 

"We are excited to work with Next Science and will commence private label marketing of the solution for plastic surgery in early 2022," said Antony Koblish, President and CEO of TELA Bio. "Including this novel infection control solution into our product portfolio will expand our service offerings and diversify our supplier base as we continue to create a market-leading soft tissue restoration portfolio. Surgical site infections present a significant risk to patients and are especially troubling in plastic surgery procedures where tissue preservation is critical."

 

Commenting on the agreement, Judith Mitchell, CEO of Next Science Limited said, "We are delighted to expand our commercial footprint through the TELA Bio sales organization. TELA Bio has a track record of success in bringing new technologies into the market and are known for their focus and drive. TELA Bio goes to market through a direct sales force to service the US plastics market. We expect this partnership will help deliver this groundbreaking technology to the hands of surgeons and aligns with Next Science's overall mission of healing patients and saving lives."

 

About Next Science

 

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development center in Florida, USA. Established in 2012 with a mission of healing patients and saving lives, the Company's primary focus is on the development and commercialization of its proprietary XBIOTM technology to reduce the impact of biofilm based infections in human health. XBIO is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO technology. Website: www.nextscience.com.

 

 

 

 

About TELA Bio, Inc.

 

TELA Bio Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The Company is committed to providing patients with advanced, economically effective biologic material repair solutions to minimize long-term exposure to permanent synthetic materials and improve clinical outcomes. TELA Bio's OviTex® and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. For more information, visit www.telabio.com.

 

Caution Regarding Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

 

Investor Contact

Greg Chodaczek

347-620-7010 
ir@telabio.com

 

 

 

EX-101.SCH 3 tela-20211101.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 tela-20211101_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 tela-20211101_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2131467d1_ex99-1img001.jpg GRAPHIC begin 644 tm2131467d1_ex99-1img001.jpg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end XML 7 tm2131467d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001561921 2021-11-01 2021-11-01 iso4217:USD shares iso4217:USD shares 0001561921 false 8-K 2021-11-01 TELA Bio, Inc. DE 001-37526 45-5320061 1 Great Valley Parkway Suite 24 Malvern PA 19355 484 320-2930 false false false false Common Stock, par value $0.001 per share TELA NASDAQ true true false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Nov. 01, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 01, 2021
Entity File Number 001-37526
Entity Registrant Name TELA Bio, Inc.
Entity Central Index Key 0001561921
Entity Tax Identification Number 45-5320061
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1 Great Valley Parkway
Entity Address, Address Line Two Suite 24
Entity Address, City or Town Malvern
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19355
City Area Code 484
Local Phone Number 320-2930
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol TELA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://telabio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2131467d1_8k.htm tela-20211101.xsd tela-20211101_lab.xml tela-20211101_pre.xml tm2131467d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2131467d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2131467d1_8k.htm" ] }, "labelLink": { "local": [ "tela-20211101_lab.xml" ] }, "presentationLink": { "local": [ "tela-20211101_pre.xml" ] }, "schema": { "local": [ "tela-20211101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "TELA", "nsuri": "http://telabio.com/20211101", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2131467d1_8k.htm", "contextRef": "From2021-11-01to2021-11-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://telabio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2131467d1_8k.htm", "contextRef": "From2021-11-01to2021-11-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://telabio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-132339-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-132339-xbrl.zip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end